MWNA
CRBP icon

Marshall Wace North America’s Corbus Pharmaceuticals CRBP Stock Holding History

Marshall Wace North America’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-360
Closed -$66K – 1432
2018
Q1 		$66K Buy
+360
New +$80.9K ﹤0.01% 1379

Other funds holding CRBP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Marshall Wace North America's CRBP Position: Q2 2018 in Review

Marshall Wace North America sold out of Corbus Pharmaceuticals (CRBP) in Q2 2018, closing a stake of 360 shares — an estimated $66K sold.

Marshall Wace North America first reported a position in CRBP in Q1 2018 and held it in 1 quarter. The position peaked at $66K in Q1 2018. 82 funds tracked by Wall St. Rank hold CRBP as of Q2 2018.

  • Marshall Wace North America reported no remaining Corbus Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Marshall Wace North America sold 360 Corbus Pharmaceuticals shares in Q2 2018, an estimated $66K.
  • Marshall Wace North America first reported a position in Corbus Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Marshall Wace North America's Corbus Pharmaceuticals position peaked at $66K in Q1 2018.
  • 82 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2018.

Based on Marshall Wace North America's 13F filing for Q2 2018, filed 14 Aug 2018.